胸腺法新用于治疗慢性丙型肝炎感染。

Thymalfasin for the treatment of chronic hepatitis C infection.

作者信息

Rustgi Vinod K

机构信息

Department of Medicine and Surgery, Georgetown University Medical Center, 8316 Arlington Blvd., Ste 515, Fairfax, VA 22031, USA.

出版信息

Ann N Y Acad Sci. 2007 Sep;1112:357-67. doi: 10.1196/annals.1415.034. Epub 2007 Jun 28.

DOI:10.1196/annals.1415.034

PMID:17600289

Abstract

The purpose of this review article is to examine previous and ongoing studies of thymalfasin in combination with peginterferon-alpha2a and peginterferon-alpha2a plus ribavirin in difficult-to-treat hepatitis C virus (HCV) patients. The following studies will be reviewed in detail: (1) Sherman and colleagues conducted a study in 109 HCV RNA positive HVC patients comparing the combination of thymalfasin + IFN versus IFN alone versus placebo. (2) Rustgi et al. evaluated the efficacy and safety of thymalfasin and peg-IFN-alpha2a in 31 genotype 1, high viral load, HCV nonresponders in a 12-week viral kinetic study. (3) Di Bisceglie, Sherman et al. performed a study of previous HCV nonresponders being retreated with either peginterferon-alpha2a plus thymalfasin or peginterferon-alpha2a plus placebo. (4) Poo and colleagues in Mexico evaluated triple combination therapy using thymalfasin, peginterferon-alpha2a, and ribavirin for the treatment of Hispanic HCV nonresponders.

摘要

这篇综述文章的目的是研究胸腺法新与聚乙二醇干扰素α-2a联合应用以及聚乙二醇干扰素α-2a加利巴韦林在难治性丙型肝炎病毒（HCV）患者中的既往和正在进行的研究。以下研究将被详细综述：（1）谢尔曼及其同事对109例HCV RNA阳性的HVC患者进行了一项研究，比较了胸腺法新+干扰素联合治疗与单用干扰素以及安慰剂的疗效。（2）拉斯吉等人在一项为期12周的病毒动力学研究中，评估了胸腺法新和聚乙二醇干扰素α-2a对31例基因1型、高病毒载量、HCV无应答者的疗效和安全性。（3）迪·比斯切利、谢尔曼等人对既往HCV无应答者进行了一项研究，这些患者再次接受聚乙二醇干扰素α-2a加胸腺法新或聚乙二醇干扰素α-2a加安慰剂治疗。（4）墨西哥的普等人评估了胸腺法新、聚乙二醇干扰素α-2a和利巴韦林三联疗法对西班牙裔HCV无应答者的治疗效果。